Lung Cancer
Volume 66, Issue 3 , Pages 333-337 , December 2009

Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study

  • V. Surmont

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 10 7041437; fax: +31 10 7041044.
    • ,
  • J.G. Aerts

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • Department of Pulmonology, Amphia Hospital, 4800 RK Breda, The Netherlands
    • ,
  • E. Pouw

      Affiliations

    • Department of Pulmonology, Groene Hartziekenhuis, 2803 HH Gouda, The Netherlands
    • ,
  • K.Y. Tan

      Affiliations

    • Department of Pulmonology, Sint-Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
    • ,
  • R. Vernhout

      Affiliations

    • Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    • ,
  • J. Gras

      Affiliations

    • Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    • ,
  • J. Salomé

      Affiliations

    • Department of Pulmonology, Sint-Franciscus Gasthuis, 3045 PM Rotterdam, The Netherlands
    • ,
  • T. Pronk

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • ,
  • P.I.M. Schmitz

      Affiliations

    • Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    • ,
  • H. Hoogsteden

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • ,
  • R.J. van Klaveren

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands

Received 31 December 2008 ,Revised 19 February 2009 ,Accepted 19 February 2009.

References 

  1. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  2. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus best supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(13):1074–1080
  3. Tjan-Heijnen VC, Groen HJ, Schramel FM, et al. Consensus conference on palliative treatment of stage IV non-small cell lung cancer. Consensus meeting of the Netherlands Society for Medical Oncology and the Taskforce on Lung Cancer of the Dutch Society of Physicians for Lung Diseases and Tuberculosis. Neth J Med. 2001;58(2):52–61
  4. Ettinger DS. Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?. Oncologist. 2002;7:226–233
  5. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362
  6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103
  7. Hanna N, Shepherd FA, Fosella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  8. Shepherd FA, Rodrigez Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353(2):123–132
  9. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc. 2003;290(16):2149–2158
  10. Kato H, Ichinose Y, Ohta M, et al. For the Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: a randomized trial of adjuvant chemotherapy with Uracil–Tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–1721
  11. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer (abstract 7002). Proc Am Soc Clin Oncol. 2004;22:615
  12. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol. 1981;30:247–257
  13. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site action of 5-fluorouracil. Cancer Res. 1981;41:3283–3295
  14. Langer CJ. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer. 2001;14:297–301
  15. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190–196
  16. Di Maio M, Chiodini P, Georgoulias V, et al. Single agent versus combination chemotherapy as second line treatment of advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual patient data of five randomized trails. J Clin Oncol. 2008;26:[May 20 suppl.; abstr. 8052]
  17. Smith E et al. A randomized phase II study of pemetrexed versus pemetrexed-carboplatin as second line treatment for patients with advanced non-small cell lung cancer-NVALT-7, ESMO 2008.
  18. Ichinose Y, Yosimori K, Yoneda S, et al. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. For the Japanese UFT Lung Cancer Study Group. Cancer. 2000;88(2):318–323
  19. Saito J, Nakai Y, Saijo Y, et al. A phase II trial of oral UFT plus cisplatin in patients with non-small cell lung cancer. Lung Cancer. 2001;31:285–293
  20. Feliu J, Gonzalez-Baron M, Espinosa E, et al. Cisplatin and UFT modulated by leucovorin for the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol. 1996;19:121–124
  21. Saxman S, Loehrer PJ, Logie K, et al. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Investigat New Drugs. 1991;9:253–256
  22. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol. 1992;10:292–296
  23. Üner A, Coskun U, Yegin A, Yamac D, Günel N. Single agent oral etoposide in recurrent or advanced solid tumors. Turkish J Cancer. 2003;33:187–190
  24. Takechi T, Nakano K, Uchida J, Takeda S. Experimental study on the combined treatment of UFT with etoposide against mouse Lewis lung carcinoma. Gan To Kagaku Ryoho. 1993;20(February(2)):235–240
  25. Gonzalez Baron M, Espinosa E, Feliu J, et al. The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group. Oncology. 1997;11(9 Suppl. 10):109–112
  26. Hartman A-R, Grekowicz A, Carlson RW. A phase I trial of UFT+leucovorin (Orzel) and oral etoposide in metastatic breast cancer. Proc Am Soc Clin Oncol. 2002;[abstract #235]
  27. Feliu J, González Barón M, Zamora P, et al. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology. 1997;54(Suppl. 1):30–37
  28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216
  29. Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials. 1999;10:1–10
  30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958;53:457–481
  31. Rodryg R, Radj G, Maciej K, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(18):2800–2807
  32. Dubey S, Brown RL, Esmond SL, et al. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol. 2005;3:149–154
  33. Shintani Y, Ohta M, Hirabayashi H, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer. 2004;45:189–196
  34. Allegra CJ, Parr AL, Wold LE, et al. Investigation of prognostic and predictive value of thymidylate synthase and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002;20:1735–1743
  35. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki 67 and p53 in patient with Dukes B and C colon cancer: a National Cancer Institute Surgical Adjuvant Breast and Bowel Project collaboration. J Clin Oncol. 2003;21:241–250
  36. Miyoshi T, Kondo K, Toba H, et al. Predictive value of thymidylate synthase and dihydropyrimide dehydrogenase expression in tumor tissue, regarding the efficacy of potoperatively administered UFT in patients with non-small cell lung cancer. Anticancer Res. 2007;27:2641–2648
  37. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107:1589–1596
  38. Yonekura K, Basaki Y, Chikahisa L, et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999;5(8):2185–2191
  39. Basaki Y, Chikahisa L, Aoyagi K, et al. Gamma-hydroxybutylic acid (GHB) and 5-FU, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis. 2001;4:163–173

PII: S0169-5002(09)00114-7

doi: 10.1016/j.lungcan.2009.02.016

Lung Cancer
Volume 66, Issue 3 , Pages 333-337 , December 2009

Article Tools

* Image Usage & Resolution